<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND AND PURPOSE: Blockade of AMPA (alpha-amino-3-hydroxy-5-<z:chebi fb="36" ids="29309">methyl</z:chebi>-4-isoxazolepropionic acid) receptors is a good treatment option for a variety of central <z:mp ids='MP_0008912'>nervous</z:mp> system disorders </plain></SENT>
<SENT sid="1" pm="."><plain>The present study evaluated the neuroprotective and <z:chebi fb="0" ids="35623">anticonvulsant</z:chebi> effects of EGIS-8332, a non-competitive AMPA receptor <z:chebi fb="68" ids="48706">antagonist</z:chebi>, as a potential drug candidate </plain></SENT>
<SENT sid="2" pm="."><plain>EXPERIMENTAL APPROACH: AMPA <z:chebi fb="68" ids="48706">antagonist</z:chebi> effects of EGIS-8332 were measured using patch-clamp techniques </plain></SENT>
<SENT sid="3" pm="."><plain>Neuroprotective and <z:chebi fb="0" ids="35623">anticonvulsant</z:chebi> effects of EGIS-8332 were evaluated in various experimental models, relative to those of GYKI 53405 </plain></SENT>
<SENT sid="4" pm="."><plain>KEY RESULTS: EGIS-8332 inhibited AMPA currents in rat cerebellar Purkinje cells and inhibited the AMPA- and quisqualate-induced excitotoxicity in primary cultures of telencephalon neurons (IC(50)=5.1-9.0 microM), in vitro </plain></SENT>
<SENT sid="5" pm="."><plain>Good <z:chebi fb="0" ids="35623">anticonvulsant</z:chebi> actions were obtained in maximal electroshock-, sound- and chemically-induced <z:hpo ids='HP_0001250'>seizures</z:hpo> (range of ED(50)=1.4-14.0 mg kg(-1) i.p.) in mice </plain></SENT>
<SENT sid="6" pm="."><plain>Four days after transient global <z:e sem="disease" ids="C0917798" disease_type="Disease or Syndrome" abbrv="">cerebral ischaemia</z:e>, EGIS-8332 decreased <z:hpo ids='HP_0002529'>neuronal loss</z:hpo> in the hippocampal CA1 area in gerbils and rats </plain></SENT>
<SENT sid="7" pm="."><plain>EGIS-8332 dose-dependently reduced cerebral <z:mpath ids='MPATH_124'>infarct</z:mpath> size after permanent middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> in mice and rats (minimum effective dose=3 mg kg(-1) i.p.) </plain></SENT>
<SENT sid="8" pm="."><plain>Side effects of EGIS-8332 emerged much above its pharmacologically active doses </plain></SENT>
<SENT sid="9" pm="."><plain>A tendency for better efficacy of GYKI 53405 than that of EGIS-8332 was observed in <z:chebi fb="0" ids="35623">anticonvulsant</z:chebi> tests that reached statistical significance in few cases, while the contrary was perceived in <z:e sem="disease" ids="C0917798" disease_type="Disease or Syndrome" abbrv="">cerebral ischaemia</z:e> tests </plain></SENT>
<SENT sid="10" pm="."><plain>CONCLUSIONS AND IMPLICATIONS: EGIS-8332 seems suitable for further development for the treatment of <z:e sem="disease" ids="C0014544" disease_type="Disease or Syndrome" abbrv="">epilepsy</z:e>, <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischaemia</z:e> and <z:hpo ids='HP_0001297'>stroke</z:hpo> based on its efficacy in a variety of experimental <z:e sem="disease" ids="C0684309" disease_type="Experimental Model of Disease" abbrv="">disease models</z:e>, and on its low side effect potential </plain></SENT>
</text></document>